Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227053 · ClinicalTrials.gov registry record
STOP AF First Post-Approval Study
A clinical trial of Paroxysmal Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions.
- Recruiting
- Registry status
- 200
- Enrollment target
- 13
- Study locations
NCT05227053 is a study of Paroxysmal Atrial Fibrillation that is actively recruiting participants, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 200 participants, below the 851-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (76% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT05227053, a study of Paroxysmal Atrial Fibrillation, is actively recruiting participants, sponsored by Medtronic Cardiac Ablation Solutions.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 13
- Study locations
Study Summary
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Conditions Studied
Interventions
- DEVICE Arctic Front™ Cardiac Cryoablation Catheter
Study Locations (13)
Florida
- BayCare Medical Group Cardiology - Clearwater
- Heart Rhythm Solutions - Davie
Tennessee
- Stern Cardiovascular Foundation - Germantown
- University of Tennessee Methodist Physicians - Memphis
Alaska
- Alaska Heart Institute - Anchorage
Connecticut
- Cardiology Associates of Fairfield County - Stamford
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Iowa
- Iowa Heart - West Des Moines
Louisiana
- Our Lady of the Lake - Baton Rouge
Massachusetts
- Southcoast Health System - North Dartmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2028-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227053
The ClinicalTrials.gov registry entry for NCT05227053 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 851-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (76% lower). The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Arctic Front™ Cardiac Cryoablation Catheter is the first listed.
NCT05227053 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Florida, Tennessee, Alaska.
Frequently Asked Questions
What is clinical trial NCT05227053 about?
NCT05227053 is a clinical study titled "STOP AF First Post-Approval Study". The STOP AF First PAS is a prospective, global, multi-center, observational trial.
What is the current status of trial NCT05227053?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-04-28. Estimated completion is 2028-04.
What conditions does trial NCT05227053 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT05227053?
The interventions under investigation include: Arctic Front™ Cardiac Cryoablation Catheter (DEVICE).
Who is sponsoring clinical trial NCT05227053?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227053 being conducted?
This trial has 13 study locations across Alaska, Connecticut, District of Columbia, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.